Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The obvious problem with a 12-18 month sales cycle is the lack of revenue. The more insidious danger for a bootstrapper is the slow feedback loop. Waiting over a year to learn if your product solves a real problem at the right price is an unacceptable risk when you could be iterating and learning much faster.
Related Insights
The idea that enterprise sales average 12-18 months is a misleading myth. Sales cycles follow a power law: if you're solving a C-level executive's number one priority, the deal closes in weeks. Anything else gets deprioritized and drags on for a year or more.
While incumbents sell roadmaps, startups can collapse enterprise sales cycles by demonstrating a fully functional product that is provably better *today*. Showing a live, superior solution turns a year-long procurement process into a 60-day sprint for motivated buyers.
If a large customer drags out a pilot indefinitely, it's a sign that your solution isn't solving a visceral, high-priority pain. When the need is urgent, enterprises will "bulldoze" through internal bureaucracy to get the product into production quickly.
Early-stage startups can't afford to be strung along by enterprise prospects. The goal isn't just to close deals, but to get feedback quickly. Founders must design a sales process that forces a decision, because a "long maybe will kill you." It's better to get a fast "no" and move on.
Don't accept industry norms like mandatory pilots or lengthy legal reviews as unchangeable facts. The fastest-growing companies creatively design their sales process, product, and initial offerings to eliminate these hurdles, dramatically shortening their sales cycle times.
Startups consistently underestimate sales cycles with large hospital systems. Due to risk aversion and complex approval processes designed to ensure patient safety, what seems like a three-month process will likely take nine months. Founders must build this 3x buffer into their financial planning to survive.
For bootstrapped startups in industries with long sales cycles and sparse feedback, like healthcare, building speculatively is extremely risky. The safest path is to de-risk development completely by only investing engineering time into features or customizations that a customer has already committed to and paid for.
The reality of hospital value analysis committees means product adoption takes years. Entrepreneurs must build this lengthy timeline into financial models and fundraising to ensure survival, rather than projecting rapid uptake.
As Eleven Labs shifted to enterprise, the long 6-12 month sales cycles caused skepticism among its fast-paced PLG teams. To maintain morale, leadership had to actively shield the teams from the lengthy process, asking for trust until the enterprise deals began to materialize and prove the strategy.
Believing you must *convince* the market leads to a dangerous product strategy: building a feature-rich platform to persuade buyers. This delays sales, burns capital, and prevents learning. A "buyer pull" approach focuses on building the minimum product needed to solve one pre-existing problem.